Skip to main content
Top
Published in: European Journal of Medical Research 1/2022

Open Access 01-12-2022 | Adenovirus | Research

Splenectomy induces biochemical remission and regeneration in experimental murine autoimmune hepatitis

Authors: Janine Dywicki, Laura Elisa Buitrago-Molina, Fatih Noyan, Jerome Schlue, Konstantinos Iordanidis, Michael P. Manns, Heiner Wedemeyer, Elmar Jaeckel, Matthias Hardtke-Wolenski

Published in: European Journal of Medical Research | Issue 1/2022

Login to get access

Abstract

Autoimmune hepatitis (AIH) is a chronic immune-mediated inflammatory liver disease. It is known that AIH originates not from the spleen but from the liver itself. Nonetheless, most details of the etiology and pathophysiology are unknown. We induced experimental murine AIH (emAIH) in NOD/Ltj mice by single administration of a replication-deficient adenovirus and performed splenectomy during late-stage disease. Biochemical disease remission occurred, which was characterized by improvement in transaminase levels. The causes of this remission included a shift in the transcriptomic signature of serum proteins toward regeneration. At the cellular level, there was a marked decrease in activated CD8+ T cells and an increase in intrahepatic regulatory T cells (Tregs). Here, intrahepatic Treg numbers correlated with biochemical remission. Notably, an imbalance in the T-cell/B-cell ratio was observed, with a disproportionate increase in total B cells. In summary, intrahepatic increases in Tregs, biochemical remission, and regeneration could be induced by splenectomy in the late stage of emAIH.
Literature
1.
go back to reference Buitrago-Molina LE, et al. Splenectomy prior to experimental induction of autoimmune hepatitis promotes more severe hepatic inflammation, production of IL-17 and apoptosis. Biomedicines. 2021;9(1):58.CrossRef Buitrago-Molina LE, et al. Splenectomy prior to experimental induction of autoimmune hepatitis promotes more severe hepatic inflammation, production of IL-17 and apoptosis. Biomedicines. 2021;9(1):58.CrossRef
2.
go back to reference Dywicki J, et al. Autoimmune hepatitis induction can occur in the liver. Liver Int. 2020;40(2):377–81.CrossRef Dywicki J, et al. Autoimmune hepatitis induction can occur in the liver. Liver Int. 2020;40(2):377–81.CrossRef
3.
go back to reference Bowen DG, et al. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest. 2004;114(5):701–12.CrossRef Bowen DG, et al. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest. 2004;114(5):701–12.CrossRef
4.
go back to reference Derkow K, et al. Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology. 2007;46(4):1155–65.CrossRef Derkow K, et al. Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology. 2007;46(4):1155–65.CrossRef
5.
go back to reference Hardtke-Wolenski M, et al. The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development. J Autoimmun. 2017;78:39–45.CrossRef Hardtke-Wolenski M, et al. The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development. J Autoimmun. 2017;78:39–45.CrossRef
6.
go back to reference de Boer YS, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014;147(2):443–52.CrossRef de Boer YS, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014;147(2):443–52.CrossRef
7.
go back to reference Czaja AJ, et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105(5):1502–7.CrossRef Czaja AJ, et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105(5):1502–7.CrossRef
8.
go back to reference Agarwal K, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology. 2000;31(1):49–53.CrossRef Agarwal K, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology. 2000;31(1):49–53.CrossRef
9.
go back to reference Hardtke-Wolenski M, et al. Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells. Hepatology. 2013;58(2):718–28.CrossRef Hardtke-Wolenski M, et al. Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells. Hepatology. 2013;58(2):718–28.CrossRef
10.
go back to reference European Association for the Study of the, L. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004.CrossRef European Association for the Study of the, L. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004.CrossRef
11.
go back to reference Mack CL, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671–722.CrossRef Mack CL, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671–722.CrossRef
12.
go back to reference Manns MP, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–213.CrossRef Manns MP, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–213.CrossRef
13.
go back to reference Hubener S, et al. Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol. 2016;14(3):445–53.CrossRef Hubener S, et al. Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol. 2016;14(3):445–53.CrossRef
14.
go back to reference Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46(4):1138–45.CrossRef Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46(4):1138–45.CrossRef
15.
go back to reference Buitrago-Molina LE, et al. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. J Autoimmun. 2021;117: 102591.CrossRef Buitrago-Molina LE, et al. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. J Autoimmun. 2021;117: 102591.CrossRef
16.
go back to reference Buitrago-Molina LE, et al. Anti-CD20 therapy alters the protein signature in experimental murine AIH, but not exclusively towards regeneration. Cells. 2021;10(6):1471.CrossRef Buitrago-Molina LE, et al. Anti-CD20 therapy alters the protein signature in experimental murine AIH, but not exclusively towards regeneration. Cells. 2021;10(6):1471.CrossRef
17.
go back to reference Kuehn HA, Weinreich J. Immunological problems in chronic hepatitis and liver cirrhosis. Dtsch Med Wochenschr. 1964;89:723–30.CrossRef Kuehn HA, Weinreich J. Immunological problems in chronic hepatitis and liver cirrhosis. Dtsch Med Wochenschr. 1964;89:723–30.CrossRef
18.
go back to reference Gramlich F. Splenectomy in chronic aggressive hepatitis. Dtsch Med J. 1969;20(16):527–30. Gramlich F. Splenectomy in chronic aggressive hepatitis. Dtsch Med J. 1969;20(16):527–30.
19.
go back to reference Dywicki J, et al. The detrimental role of regulatory T cells in nonalcoholic steatohepatitis. Hepatol Commun. 2021;6:320.CrossRef Dywicki J, et al. The detrimental role of regulatory T cells in nonalcoholic steatohepatitis. Hepatol Commun. 2021;6:320.CrossRef
20.
go back to reference Endig J, et al. Dual role of the adaptive immune system in liver injury and hepatocellular carcinoma development. Cancer Cell. 2016;30(2):308–23.CrossRef Endig J, et al. Dual role of the adaptive immune system in liver injury and hepatocellular carcinoma development. Cancer Cell. 2016;30(2):308–23.CrossRef
21.
go back to reference Dywicki J, et al. Hepatic T cell tolerance induction in an inflammatory environment. Dig Dis. 2018;36(2):156–66.CrossRef Dywicki J, et al. Hepatic T cell tolerance induction in an inflammatory environment. Dig Dis. 2018;36(2):156–66.CrossRef
22.
go back to reference Romermann D, et al. Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury. Liver Int. 2020;40(5):1225–38.CrossRef Romermann D, et al. Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury. Liver Int. 2020;40(5):1225–38.CrossRef
23.
go back to reference Assarsson E, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4): e95192.CrossRef Assarsson E, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4): e95192.CrossRef
24.
go back to reference Fodor O, Tanasescu R. Post-hepatitis immunological hemolytic anemia. The effect of treatment with cortisone like drugs and of splenectomy. Med Interna (Bucur). 1962;14:1469–78. Fodor O, Tanasescu R. Post-hepatitis immunological hemolytic anemia. The effect of treatment with cortisone like drugs and of splenectomy. Med Interna (Bucur). 1962;14:1469–78.
25.
go back to reference Maruoka R, et al. Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. Gastroenterology. 2013;145(1):209–20.CrossRef Maruoka R, et al. Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. Gastroenterology. 2013;145(1):209–20.CrossRef
26.
go back to reference Taubert R, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol. 2014;61(5):1106–14.CrossRef Taubert R, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol. 2014;61(5):1106–14.CrossRef
27.
go back to reference Taubert R, et al. Enrichment of regulatory T cells in acutely rejected human liver allografts. Am J Transplant. 2012;12(12):3425–36.CrossRef Taubert R, et al. Enrichment of regulatory T cells in acutely rejected human liver allografts. Am J Transplant. 2012;12(12):3425–36.CrossRef
28.
go back to reference Peiseler M, et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol. 2012;57(1):125–32.CrossRef Peiseler M, et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol. 2012;57(1):125–32.CrossRef
29.
go back to reference Jones-Youngblood SL, et al. Effect of the expression of a hepatocyte-specific MHC molecule in transgenic mice on T cell tolerance. J Immunol. 1990;144(4):1187–95. Jones-Youngblood SL, et al. Effect of the expression of a hepatocyte-specific MHC molecule in transgenic mice on T cell tolerance. J Immunol. 1990;144(4):1187–95.
30.
go back to reference Morahan G, et al. Expression in transgenic mice of class I histocompatibility antigens controlled by the metallothionein promoter. Proc Natl Acad Sci U S A. 1989;86(10):3782–6.CrossRef Morahan G, et al. Expression in transgenic mice of class I histocompatibility antigens controlled by the metallothionein promoter. Proc Natl Acad Sci U S A. 1989;86(10):3782–6.CrossRef
31.
go back to reference Moriyama T, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science. 1990;248(4953):361–4.CrossRef Moriyama T, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science. 1990;248(4953):361–4.CrossRef
32.
go back to reference Wirth S, et al. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice. J Immunol. 1995;154(5):2504–15. Wirth S, et al. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice. J Immunol. 1995;154(5):2504–15.
33.
go back to reference Pandey SP, et al. Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis. Cell Host Microbe. 2022;30(7):1003–19.CrossRef Pandey SP, et al. Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis. Cell Host Microbe. 2022;30(7):1003–19.CrossRef
34.
go back to reference Limmer A, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med. 2000;6(12):1348–54.CrossRef Limmer A, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med. 2000;6(12):1348–54.CrossRef
35.
go back to reference Liberal R, et al. Cutting edge issues in autoimmune hepatitis. J Autoimmun. 2016;75:6–19.CrossRef Liberal R, et al. Cutting edge issues in autoimmune hepatitis. J Autoimmun. 2016;75:6–19.CrossRef
36.
go back to reference Liberal R, Vergani D, Mieli-Vergani G. Update on autoimmune hepatitis. J Clin Transl Hepatol. 2015;3(1):42–52.CrossRef Liberal R, Vergani D, Mieli-Vergani G. Update on autoimmune hepatitis. J Clin Transl Hepatol. 2015;3(1):42–52.CrossRef
37.
go back to reference Beland K, et al. Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells. Hepatology. 2015;62(5):1511–23.CrossRef Beland K, et al. Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells. Hepatology. 2015;62(5):1511–23.CrossRef
Metadata
Title
Splenectomy induces biochemical remission and regeneration in experimental murine autoimmune hepatitis
Authors
Janine Dywicki
Laura Elisa Buitrago-Molina
Fatih Noyan
Jerome Schlue
Konstantinos Iordanidis
Michael P. Manns
Heiner Wedemeyer
Elmar Jaeckel
Matthias Hardtke-Wolenski
Publication date
01-12-2022
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2022
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-022-00933-3

Other articles of this Issue 1/2022

European Journal of Medical Research 1/2022 Go to the issue